Extracellular vesicles: Navigating new frontiers in glioblastoma therapy
- 1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 02115, USA; Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 02115, USA
- 2Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 02115, USA; Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 02115, USA; Corresponding authors.
- 3Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 02115, USA; Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 02115, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, 02138, USA; Corresponding authors.
Abstract
The profound challenge in treating glioblastoma (GBM) stems from a confluence of obstacles. The formidable blood-brain barrier (BBB) limits drug access, while the tumor’s inherent inter- and intra-tumoral heterogeneity, profound immunosuppression, invasive growth, and frequent recurrence all contribute to dismal prognoses and severely hamper therapeutic efficacy. Extracellular vesicles (EVs), naturally occurring nano-sized messengers between cells, offer a novel therapeutic avenue by addressing these key obstacles. Their inherent ability to cross the BBB, deliver diverse cargo, and modulate the immune system positions them as promising vehicles for targeted drug delivery, immunotherapy, and even cancer vaccination. This review explores the therapeutic potential of various EV subtypes, including those derived from dendritic cells, T cells, brain endothelial cells, and mesenchymal stem cells, emphasizing their unique properties and preclinical successes in GBM models. We discuss current engineering strategies to enhance EV targeting, delivery, and therapeutic efficacy, alongside the emerging potential of EV-based cancer vaccines for GBM. Finally, we address the challenges and future directions of EV-based therapies for GBM, including standardized isolation and characterization protocols, scalable production, and rigorous safety assessments. Despite these challenges, the burgeoning field of EV research holds immense promise for transforming GBM treatment paradigms and improving patient outcomes.
Related
- Oncolytic Virus-Engineered Extracellular Vesicles Rewire Glioblastoma Immunity.
- Senescent Cell‐Derived Extracellular Vesicles in Therapy‐Induced Senescence: Immune Remodelling and Emerging Links to Mitochondrial Stress in Cancer
- Exosomes and Extracellular Vesicles in Oncology: Next-Generation Smart Nanocarriers for Precision Cancer Therapy.
- Editorial: Investigating the role of extracellular vesicles in cardiovascular disease mechanisms
- ICAM-5: A marker for neuronally derived extracellular vesicles
BibTeX
@article{mendonca2026extracellular,
title = {{Extracellular vesicles: Navigating new frontiers in glioblastoma therapy}},
author = {Natalia Claire Mendonca and Longsha Liu and Kok-Siong Chen and Khalid Shah},
journal = {Neurotherapeutics},
year = {2026},
month = oct,
doi = {10.1016/j.neurot.2026.e01036},
url = {https://doi.org/10.1016/j.neurot.2026.e01036},
note = {CC BY},
}
RIS
TY - JOUR
TI - Extracellular vesicles: Navigating new frontiers in glioblastoma therapy
AU - Natalia Claire Mendonca
AU - Longsha Liu
AU - Kok-Siong Chen
AU - Khalid Shah
PY - 2026
DA - 2026/10/24
JO - Neurotherapeutics
DO - 10.1016/j.neurot.2026.e01036
UR - https://doi.org/10.1016/j.neurot.2026.e01036
AB - The profound challenge in treating glioblastoma (GBM) stems from a confluence of obstacles. The formidable blood-brain barrier (BBB) limits drug access, while the tumor’s inherent inter- and intra-tumoral heterogeneity, profound immunosuppression, invasive growth, and frequent recurrence all contribute to dismal prognoses and severely hamper therapeutic efficacy. Extracellular vesicles (EVs), naturally occurring nano-sized messengers between cells, offer a novel therapeutic avenue by addressing these key obstacles. Their inherent ability to cross the BBB, deliver diverse cargo, and modulate the immune system positions them as promising vehicles for targeted drug delivery, immunotherapy, and even cancer vaccination. This review explores the therapeutic potential of various EV subtypes, including those derived from dendritic cells, T cells, brain endothelial cells, and mesenchymal stem cells, emphasizing their unique properties and preclinical successes in GBM models. We discuss current engineering strategies to enhance EV targeting, delivery, and therapeutic efficacy, alongside the emerging potential of EV-based cancer vaccines for GBM. Finally, we address the challenges and future directions of EV-based therapies for GBM, including standardized isolation and characterization protocols, scalable production, and rigorous safety assessments. Despite these challenges, the burgeoning field of EV research holds immense promise for transforming GBM treatment paradigms and improving patient outcomes.
SN - 1878-7479
SN - 1933-7213
ER -